Global Long-acting Anti-HIV Drugs Market Growth 2026-2032
The global Long-acting Anti-HIV Drugs market size is predicted to grow from US$ 295 million in 2025 to US$ 815 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.
Long-acting anti-HIV drugs are antiretroviral products formulated with extended-release technologies to maintain therapeutic drug exposure over prolonged intervals, enabling HIV treatment (ART) or prevention (PrEP) to be delivered weekly, monthly, or even less frequently rather than requiring daily oral dosing. They are designed to address real-world adherence and stigma-related barriers: durable viral suppression depends on consistent medication intake, yet missed doses, treatment fatigue, irregular routines, and privacy concerns can undermine outcomes and increase transmission risk; long-acting dosing reduces pill burden and the day-to-day “reminder” of therapy, improving continuity of care and quality of life while expanding prevention options for people who struggle with daily PrEP. Historically, HIV care progressed from early multi-pill oral regimens toward potent combination therapies with better safety and resistance profiles, after which innovation increasingly focused on delivery and adherence; advances in formulation science and drug-delivery platforms enabled extended-release approaches such as intramuscular or subcutaneous injections and implants, using technologies like nanosuspensions, microspheres, lipid/polymer carriers, or controlled-release matrices to provide predictable exposure over time. The upstream supply chain typically spans active pharmaceutical ingredients and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), formulation excipients (biodegradable polymers such as PLGA, lipids, surfactants, stabilizers, and release-controlling matrices), and sterile delivery/packaging inputs (prefilled syringes and needle components, rubber stoppers and seals, sterile filters, glass or high-barrier polymer containers), along with critical manufacturing and quality-control “components” (single-use fluid paths, pumps/valves, isolator and HEPA filtration elements, in-line sensors for particle size/viscosity, cold-chain temperature indicators). Because long-acting products place tighter constraints on sterility assurance, particle-size distribution, release-profile consistency, and storage stability, upstream material quality systems and regulatory-grade traceability are often decisive for batch release and reliable commercial supply.In 2025, global production capacity for long-acting anti-HIV drugs reached 150,000 doses, while sales totaled 130,200 doses. The average selling price was approximately USD 2,312 per dose, and gross margins across manufacturers were in the range of 60%–70%.
In the current market landscape, long-acting anti-HIV therapy and prevention are moving from “clinically feasible” to “real-world deployable,” with commercialization increasingly shaped by adherence outcomes, service accessibility, and reimbursement pathways rather than efficacy alone. In practice, adoption tends to concentrate in populations where daily dosing is challenging due to unstable routines, pill fatigue, or privacy concerns, while broader rollout depends heavily on care delivery readiness—standardized visit scheduling, repeatable injection workflows, cold-chain and inventory control, and robust management of adverse events and the so-called pharmacokinetic “tail.” As clinicians and patients gain experience, conversations are shifting from whether long-acting options work to who benefits most, how to switch safely, and how to sustain therapy over time, with stronger integration into sexual health clinics, community programs, and public health initiatives—making “drug plus service” the de facto product.
Looking ahead, innovation is likely to track toward longer dosing intervals, more stable exposure, higher resistance barriers, simpler administration, and a better patient experience, supported by multiple delivery platforms in parallel. On the regimen side, development momentum favors combinations and strategies that maintain a strong barrier to resistance and reduce vulnerability during transitions or missed visits. On the formulation side, continued optimization of nanosuspensions, microspheres, lipid/polymer carriers, and implants aims to improve injection volume, local tolerability, release predictability, and storage/transport stability. On the system side, care models will diversify beyond conventional clinic injections, pairing long-acting dosing with telehealth follow-up, community-based administration, mobile care teams, and digital tools for appointment and adherence management, creating delivery pathways that better match local resource constraints. In prevention settings, long-acting options may enable more sustainable coverage for higher-risk groups by reducing discontinuation and improving continuity of protection.
The market is propelled and constrained by forces that operate simultaneously. Key drivers include public health priorities around sustained suppression and sustained prevention, patient demand for improved quality of life and discretion, and payer interest in avoiding lapses that lead to complications and onward transmission; on the industry side, maturation of formulation platforms, sterile manufacturing capabilities, and increasingly standardized service delivery all support uptake. Major barriers include access limitations inherent to facility-based administration, operational burdens from cold-chain and inventory requirements, management of injection-site reactions and long-term tolerability, and the resistance and transmission risks associated with interruption during the drug “tail,” which necessitate disciplined screening, follow-up, and contingency plans. Regional variation in regulation, procurement, and reimbursement can further slow penetration, while stigma, information gaps, and suboptimal service experiences may undermine persistence. As a result, competitive advantage will increasingly hinge not only on the molecule, but on end-to-end capabilities across screening, dosing, follow-up, supply assurance, and risk management.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Anti-HIV Drugs Industry Forecast” looks at past sales and reviews total world Long-acting Anti-HIV Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Anti-HIV Drugs sales for 2026 through 2032. With Long-acting Anti-HIV Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Anti-HIV Drugs industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Anti-HIV Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Anti-HIV Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Anti-HIV Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Anti-HIV Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Anti-HIV Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Anti-HIV Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Long-acting Anti-HIV Drugs market?
What factors are driving Long-acting Anti-HIV Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Anti-HIV Drugs market opportunities vary by end market size?
How does Long-acting Anti-HIV Drugs break out by Type, by Application?
Long-acting anti-HIV drugs are antiretroviral products formulated with extended-release technologies to maintain therapeutic drug exposure over prolonged intervals, enabling HIV treatment (ART) or prevention (PrEP) to be delivered weekly, monthly, or even less frequently rather than requiring daily oral dosing. They are designed to address real-world adherence and stigma-related barriers: durable viral suppression depends on consistent medication intake, yet missed doses, treatment fatigue, irregular routines, and privacy concerns can undermine outcomes and increase transmission risk; long-acting dosing reduces pill burden and the day-to-day “reminder” of therapy, improving continuity of care and quality of life while expanding prevention options for people who struggle with daily PrEP. Historically, HIV care progressed from early multi-pill oral regimens toward potent combination therapies with better safety and resistance profiles, after which innovation increasingly focused on delivery and adherence; advances in formulation science and drug-delivery platforms enabled extended-release approaches such as intramuscular or subcutaneous injections and implants, using technologies like nanosuspensions, microspheres, lipid/polymer carriers, or controlled-release matrices to provide predictable exposure over time. The upstream supply chain typically spans active pharmaceutical ingredients and key intermediates (specialty chemicals, chiral reagents, solvents, catalysts), formulation excipients (biodegradable polymers such as PLGA, lipids, surfactants, stabilizers, and release-controlling matrices), and sterile delivery/packaging inputs (prefilled syringes and needle components, rubber stoppers and seals, sterile filters, glass or high-barrier polymer containers), along with critical manufacturing and quality-control “components” (single-use fluid paths, pumps/valves, isolator and HEPA filtration elements, in-line sensors for particle size/viscosity, cold-chain temperature indicators). Because long-acting products place tighter constraints on sterility assurance, particle-size distribution, release-profile consistency, and storage stability, upstream material quality systems and regulatory-grade traceability are often decisive for batch release and reliable commercial supply.In 2025, global production capacity for long-acting anti-HIV drugs reached 150,000 doses, while sales totaled 130,200 doses. The average selling price was approximately USD 2,312 per dose, and gross margins across manufacturers were in the range of 60%–70%.
In the current market landscape, long-acting anti-HIV therapy and prevention are moving from “clinically feasible” to “real-world deployable,” with commercialization increasingly shaped by adherence outcomes, service accessibility, and reimbursement pathways rather than efficacy alone. In practice, adoption tends to concentrate in populations where daily dosing is challenging due to unstable routines, pill fatigue, or privacy concerns, while broader rollout depends heavily on care delivery readiness—standardized visit scheduling, repeatable injection workflows, cold-chain and inventory control, and robust management of adverse events and the so-called pharmacokinetic “tail.” As clinicians and patients gain experience, conversations are shifting from whether long-acting options work to who benefits most, how to switch safely, and how to sustain therapy over time, with stronger integration into sexual health clinics, community programs, and public health initiatives—making “drug plus service” the de facto product.
Looking ahead, innovation is likely to track toward longer dosing intervals, more stable exposure, higher resistance barriers, simpler administration, and a better patient experience, supported by multiple delivery platforms in parallel. On the regimen side, development momentum favors combinations and strategies that maintain a strong barrier to resistance and reduce vulnerability during transitions or missed visits. On the formulation side, continued optimization of nanosuspensions, microspheres, lipid/polymer carriers, and implants aims to improve injection volume, local tolerability, release predictability, and storage/transport stability. On the system side, care models will diversify beyond conventional clinic injections, pairing long-acting dosing with telehealth follow-up, community-based administration, mobile care teams, and digital tools for appointment and adherence management, creating delivery pathways that better match local resource constraints. In prevention settings, long-acting options may enable more sustainable coverage for higher-risk groups by reducing discontinuation and improving continuity of protection.
The market is propelled and constrained by forces that operate simultaneously. Key drivers include public health priorities around sustained suppression and sustained prevention, patient demand for improved quality of life and discretion, and payer interest in avoiding lapses that lead to complications and onward transmission; on the industry side, maturation of formulation platforms, sterile manufacturing capabilities, and increasingly standardized service delivery all support uptake. Major barriers include access limitations inherent to facility-based administration, operational burdens from cold-chain and inventory requirements, management of injection-site reactions and long-term tolerability, and the resistance and transmission risks associated with interruption during the drug “tail,” which necessitate disciplined screening, follow-up, and contingency plans. Regional variation in regulation, procurement, and reimbursement can further slow penetration, while stigma, information gaps, and suboptimal service experiences may undermine persistence. As a result, competitive advantage will increasingly hinge not only on the molecule, but on end-to-end capabilities across screening, dosing, follow-up, supply assurance, and risk management.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting Anti-HIV Drugs Industry Forecast” looks at past sales and reviews total world Long-acting Anti-HIV Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting Anti-HIV Drugs sales for 2026 through 2032. With Long-acting Anti-HIV Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting Anti-HIV Drugs industry.
This Insight Report provides a comprehensive analysis of the global Long-acting Anti-HIV Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting Anti-HIV Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting Anti-HIV Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting Anti-HIV Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting Anti-HIV Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting Anti-HIV Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Single Drug
- Combination Preparation
- Short-interval Injections
- Monthly Injections
- Quarterly Injections
- Original Drug
- Generic Drug
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ViiV Healthcare
- Janssen Pharmaceuticals
- Gilead Sciences
- Theratechnologies
What is the 10-year outlook for the global Long-acting Anti-HIV Drugs market?
What factors are driving Long-acting Anti-HIV Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting Anti-HIV Drugs market opportunities vary by end market size?
How does Long-acting Anti-HIV Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-acting Anti-HIV Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Long-acting Anti-HIV Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Long-acting Anti-HIV Drugs by Country/Region, 2021, 2025 & 2032
2.2 Long-acting Anti-HIV Drugs Segment by Type
2.2.1 Single Drug
2.2.2 Combination Preparation
2.2.3 Long-acting Anti-HIV Drugs Sales by Type
2.2.3.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Long-acting Anti-HIV Drugs Sale Price by Type (2021-2026)
2.3 Long-acting Anti-HIV Drugs Segment by Dosing Interval
2.3.1 Short-interval Injections
2.3.2 Monthly Injections
2.3.3 Quarterly Injections
2.3.4 Long-acting Anti-HIV Drugs Sales by Dosing Interval
2.3.4.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Dosing Interval (2021-2026)
2.3.4.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Dosing Interval (2021-2026)
2.3.4.3 Global Long-acting Anti-HIV Drugs Sale Price by Dosing Interval (2021-2026)
2.4 Long-acting Anti-HIV Drugs Segment by Drug Properties
2.4.1 Original Drug
2.4.2 Generic Drug
2.4.3 Long-acting Anti-HIV Drugs Sales by Drug Properties
2.4.3.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Drug Properties (2021-2026)
2.4.3.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Drug Properties (2021-2026)
2.4.3.3 Global Long-acting Anti-HIV Drugs Sale Price by Drug Properties (2021-2026)
2.5 Long-acting Anti-HIV Drugs Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Other
2.5.4 Long-acting Anti-HIV Drugs Sales by Application
2.5.4.1 Global Long-acting Anti-HIV Drugs Sale Market Share by Application (2021-2026)
2.5.4.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Long-acting Anti-HIV Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Long-acting Anti-HIV Drugs Breakdown Data by Company
3.1.1 Global Long-acting Anti-HIV Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Long-acting Anti-HIV Drugs Sales Market Share by Company (2021-2026)
3.2 Global Long-acting Anti-HIV Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Long-acting Anti-HIV Drugs Revenue by Company (2021-2026)
3.2.2 Global Long-acting Anti-HIV Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Long-acting Anti-HIV Drugs Sale Price by Company
3.4 Key Manufacturers Long-acting Anti-HIV Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Anti-HIV Drugs Product Location Distribution
3.4.2 Players Long-acting Anti-HIV Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LONG-ACTING ANTI-HIV DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Long-acting Anti-HIV Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Long-acting Anti-HIV Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Long-acting Anti-HIV Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Long-acting Anti-HIV Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Long-acting Anti-HIV Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Long-acting Anti-HIV Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-acting Anti-HIV Drugs Sales Growth
4.4 APAC Long-acting Anti-HIV Drugs Sales Growth
4.5 Europe Long-acting Anti-HIV Drugs Sales Growth
4.6 Middle East & Africa Long-acting Anti-HIV Drugs Sales Growth
5 AMERICAS
5.1 Americas Long-acting Anti-HIV Drugs Sales by Country
5.1.1 Americas Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
5.1.2 Americas Long-acting Anti-HIV Drugs Revenue by Country (2021-2026)
5.2 Americas Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
5.3 Americas Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Anti-HIV Drugs Sales by Region
6.1.1 APAC Long-acting Anti-HIV Drugs Sales by Region (2021-2026)
6.1.2 APAC Long-acting Anti-HIV Drugs Revenue by Region (2021-2026)
6.2 APAC Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
6.3 APAC Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Long-acting Anti-HIV Drugs by Country
7.1.1 Europe Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
7.1.2 Europe Long-acting Anti-HIV Drugs Revenue by Country (2021-2026)
7.2 Europe Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
7.3 Europe Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-acting Anti-HIV Drugs by Country
8.1.1 Middle East & Africa Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Long-acting Anti-HIV Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drugs
10.3 Manufacturing Process Analysis of Long-acting Anti-HIV Drugs
10.4 Industry Chain Structure of Long-acting Anti-HIV Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Anti-HIV Drugs Distributors
11.3 Long-acting Anti-HIV Drugs Customer
12 WORLD FORECAST REVIEW FOR LONG-ACTING ANTI-HIV DRUGS BY GEOGRAPHIC REGION
12.1 Global Long-acting Anti-HIV Drugs Market Size Forecast by Region
12.1.1 Global Long-acting Anti-HIV Drugs Forecast by Region (2027-2032)
12.1.2 Global Long-acting Anti-HIV Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Long-acting Anti-HIV Drugs Forecast by Type (2027-2032)
12.7 Global Long-acting Anti-HIV Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.1.3 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Information
13.2.2 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.2.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Janssen Pharmaceuticals Main Business Overview
13.2.5 Janssen Pharmaceuticals Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Theratechnologies
13.4.1 Theratechnologies Company Information
13.4.2 Theratechnologies Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.4.3 Theratechnologies Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Theratechnologies Main Business Overview
13.4.5 Theratechnologies Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Long-acting Anti-HIV Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Long-acting Anti-HIV Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Long-acting Anti-HIV Drugs by Country/Region, 2021, 2025 & 2032
2.2 Long-acting Anti-HIV Drugs Segment by Type
2.2.1 Single Drug
2.2.2 Combination Preparation
2.2.3 Long-acting Anti-HIV Drugs Sales by Type
2.2.3.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Long-acting Anti-HIV Drugs Sale Price by Type (2021-2026)
2.3 Long-acting Anti-HIV Drugs Segment by Dosing Interval
2.3.1 Short-interval Injections
2.3.2 Monthly Injections
2.3.3 Quarterly Injections
2.3.4 Long-acting Anti-HIV Drugs Sales by Dosing Interval
2.3.4.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Dosing Interval (2021-2026)
2.3.4.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Dosing Interval (2021-2026)
2.3.4.3 Global Long-acting Anti-HIV Drugs Sale Price by Dosing Interval (2021-2026)
2.4 Long-acting Anti-HIV Drugs Segment by Drug Properties
2.4.1 Original Drug
2.4.2 Generic Drug
2.4.3 Long-acting Anti-HIV Drugs Sales by Drug Properties
2.4.3.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Drug Properties (2021-2026)
2.4.3.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Drug Properties (2021-2026)
2.4.3.3 Global Long-acting Anti-HIV Drugs Sale Price by Drug Properties (2021-2026)
2.5 Long-acting Anti-HIV Drugs Segment by Application
2.5.1 Hospital
2.5.2 Clinic
2.5.3 Other
2.5.4 Long-acting Anti-HIV Drugs Sales by Application
2.5.4.1 Global Long-acting Anti-HIV Drugs Sale Market Share by Application (2021-2026)
2.5.4.2 Global Long-acting Anti-HIV Drugs Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Long-acting Anti-HIV Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Long-acting Anti-HIV Drugs Breakdown Data by Company
3.1.1 Global Long-acting Anti-HIV Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Long-acting Anti-HIV Drugs Sales Market Share by Company (2021-2026)
3.2 Global Long-acting Anti-HIV Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Long-acting Anti-HIV Drugs Revenue by Company (2021-2026)
3.2.2 Global Long-acting Anti-HIV Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Long-acting Anti-HIV Drugs Sale Price by Company
3.4 Key Manufacturers Long-acting Anti-HIV Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Long-acting Anti-HIV Drugs Product Location Distribution
3.4.2 Players Long-acting Anti-HIV Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LONG-ACTING ANTI-HIV DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Long-acting Anti-HIV Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Long-acting Anti-HIV Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Long-acting Anti-HIV Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Long-acting Anti-HIV Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Long-acting Anti-HIV Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Long-acting Anti-HIV Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Long-acting Anti-HIV Drugs Sales Growth
4.4 APAC Long-acting Anti-HIV Drugs Sales Growth
4.5 Europe Long-acting Anti-HIV Drugs Sales Growth
4.6 Middle East & Africa Long-acting Anti-HIV Drugs Sales Growth
5 AMERICAS
5.1 Americas Long-acting Anti-HIV Drugs Sales by Country
5.1.1 Americas Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
5.1.2 Americas Long-acting Anti-HIV Drugs Revenue by Country (2021-2026)
5.2 Americas Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
5.3 Americas Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-acting Anti-HIV Drugs Sales by Region
6.1.1 APAC Long-acting Anti-HIV Drugs Sales by Region (2021-2026)
6.1.2 APAC Long-acting Anti-HIV Drugs Revenue by Region (2021-2026)
6.2 APAC Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
6.3 APAC Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Long-acting Anti-HIV Drugs by Country
7.1.1 Europe Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
7.1.2 Europe Long-acting Anti-HIV Drugs Revenue by Country (2021-2026)
7.2 Europe Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
7.3 Europe Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Long-acting Anti-HIV Drugs by Country
8.1.1 Middle East & Africa Long-acting Anti-HIV Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Long-acting Anti-HIV Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Long-acting Anti-HIV Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Long-acting Anti-HIV Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drugs
10.3 Manufacturing Process Analysis of Long-acting Anti-HIV Drugs
10.4 Industry Chain Structure of Long-acting Anti-HIV Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Long-acting Anti-HIV Drugs Distributors
11.3 Long-acting Anti-HIV Drugs Customer
12 WORLD FORECAST REVIEW FOR LONG-ACTING ANTI-HIV DRUGS BY GEOGRAPHIC REGION
12.1 Global Long-acting Anti-HIV Drugs Market Size Forecast by Region
12.1.1 Global Long-acting Anti-HIV Drugs Forecast by Region (2027-2032)
12.1.2 Global Long-acting Anti-HIV Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Long-acting Anti-HIV Drugs Forecast by Type (2027-2032)
12.7 Global Long-acting Anti-HIV Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.1.3 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Janssen Pharmaceuticals
13.2.1 Janssen Pharmaceuticals Company Information
13.2.2 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.2.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Janssen Pharmaceuticals Main Business Overview
13.2.5 Janssen Pharmaceuticals Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Theratechnologies
13.4.1 Theratechnologies Company Information
13.4.2 Theratechnologies Long-acting Anti-HIV Drugs Product Portfolios and Specifications
13.4.3 Theratechnologies Long-acting Anti-HIV Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Theratechnologies Main Business Overview
13.4.5 Theratechnologies Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Long-acting Anti-HIV Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Long-acting Anti-HIV Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Single Drug
Table 4. Major Players of Combination Preparation
Table 5. Global Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 6. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Long-acting Anti-HIV Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Long-acting Anti-HIV Drugs Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Short-interval Injections
Table 11. Major Players of Monthly Injections
Table 12. Major Players of Quarterly Injections
Table 13. Global Long-acting Anti-HIV Drugs Sales by Dosing Interval (2021-2026) & (K Dose)
Table 14. Global Long-acting Anti-HIV Drugs Sales Market Share by Dosing Interval (2021-2026)
Table 15. Global Long-acting Anti-HIV Drugs Revenue by Dosing Interval (2021-2026) & ($ million)
Table 16. Global Long-acting Anti-HIV Drugs Revenue Market Share by Dosing Interval (2021-2026)
Table 17. Global Long-acting Anti-HIV Drugs Sale Price by Dosing Interval (2021-2026) & (US$/Dose)
Table 18. Major Players of Original Drug
Table 19. Major Players of Generic Drug
Table 20. Global Long-acting Anti-HIV Drugs Sales by Drug Properties (2021-2026) & (K Dose)
Table 21. Global Long-acting Anti-HIV Drugs Sales Market Share by Drug Properties (2021-2026)
Table 22. Global Long-acting Anti-HIV Drugs Revenue by Drug Properties (2021-2026) & ($ million)
Table 23. Global Long-acting Anti-HIV Drugs Revenue Market Share by Drug Properties (2021-2026)
Table 24. Global Long-acting Anti-HIV Drugs Sale Price by Drug Properties (2021-2026) & (US$/Dose)
Table 25. Global Long-acting Anti-HIV Drugs Sale by Application (2021-2026) & (K Dose)
Table 26. Global Long-acting Anti-HIV Drugs Sale Market Share by Application (2021-2026)
Table 27. Global Long-acting Anti-HIV Drugs Revenue by Application (2021-2026) & ($ million)
Table 28. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2026)
Table 29. Global Long-acting Anti-HIV Drugs Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Long-acting Anti-HIV Drugs Sales by Company (2021-2026) & (K Dose)
Table 31. Global Long-acting Anti-HIV Drugs Sales Market Share by Company (2021-2026)
Table 32. Global Long-acting Anti-HIV Drugs Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Long-acting Anti-HIV Drugs Revenue Market Share by Company (2021-2026)
Table 34. Global Long-acting Anti-HIV Drugs Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Long-acting Anti-HIV Drugs Producing Area Distribution and Sales Area
Table 36. Players Long-acting Anti-HIV Drugs Products Offered
Table 37. Long-acting Anti-HIV Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Long-acting Anti-HIV Drugs Sales by Geographic Region (2021-2026) & (K Dose)
Table 41. Global Long-acting Anti-HIV Drugs Sales Market Share Geographic Region (2021-2026)
Table 42. Global Long-acting Anti-HIV Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Long-acting Anti-HIV Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Long-acting Anti-HIV Drugs Sales by Country/Region (2021-2026) & (K Dose)
Table 45. Global Long-acting Anti-HIV Drugs Sales Market Share by Country/Region (2021-2026)
Table 46. Global Long-acting Anti-HIV Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Long-acting Anti-HIV Drugs Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Dose)
Table 49. Americas Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2026)
Table 50. Americas Long-acting Anti-HIV Drugs Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 52. Americas Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 53. APAC Long-acting Anti-HIV Drugs Sales by Region (2021-2026) & (K Dose)
Table 54. APAC Long-acting Anti-HIV Drugs Sales Market Share by Region (2021-2026)
Table 55. APAC Long-acting Anti-HIV Drugs Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 57. APAC Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 58. Europe Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Dose)
Table 59. Europe Long-acting Anti-HIV Drugs Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 61. Europe Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 62. Middle East & Africa Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Dose)
Table 63. Middle East & Africa Long-acting Anti-HIV Drugs Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 65. Middle East & Africa Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 66. Key Market Drivers & Growth Opportunities of Long-acting Anti-HIV Drugs
Table 67. Key Market Challenges & Risks of Long-acting Anti-HIV Drugs
Table 68. Key Industry Trends of Long-acting Anti-HIV Drugs
Table 69. Long-acting Anti-HIV Drugs Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Long-acting Anti-HIV Drugs Distributors List
Table 72. Long-acting Anti-HIV Drugs Customer List
Table 73. Global Long-acting Anti-HIV Drugs Sales Forecast by Region (2027-2032) & (K Dose)
Table 74. Global Long-acting Anti-HIV Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Long-acting Anti-HIV Drugs Sales Forecast by Country (2027-2032) & (K Dose)
Table 76. Americas Long-acting Anti-HIV Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Long-acting Anti-HIV Drugs Sales Forecast by Region (2027-2032) & (K Dose)
Table 78. APAC Long-acting Anti-HIV Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Long-acting Anti-HIV Drugs Sales Forecast by Country (2027-2032) & (K Dose)
Table 80. Europe Long-acting Anti-HIV Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Long-acting Anti-HIV Drugs Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Middle East & Africa Long-acting Anti-HIV Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Long-acting Anti-HIV Drugs Sales Forecast by Type (2027-2032) & (K Dose)
Table 84. Global Long-acting Anti-HIV Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Long-acting Anti-HIV Drugs Sales Forecast by Application (2027-2032) & (K Dose)
Table 86. Global Long-acting Anti-HIV Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. ViiV Healthcare Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 89. ViiV Healthcare Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. ViiV Healthcare Main Business
Table 91. ViiV Healthcare Latest Developments
Table 92. Janssen Pharmaceuticals Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 94. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. Janssen Pharmaceuticals Main Business
Table 96. Janssen Pharmaceuticals Latest Developments
Table 97. Gilead Sciences Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 99. Gilead Sciences Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Gilead Sciences Main Business
Table 101. Gilead Sciences Latest Developments
Table 102. Theratechnologies Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Theratechnologies Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 104. Theratechnologies Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Theratechnologies Main Business
Table 106. Theratechnologies Latest Developments
Table 1. Long-acting Anti-HIV Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Long-acting Anti-HIV Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Single Drug
Table 4. Major Players of Combination Preparation
Table 5. Global Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 6. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Long-acting Anti-HIV Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Long-acting Anti-HIV Drugs Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Short-interval Injections
Table 11. Major Players of Monthly Injections
Table 12. Major Players of Quarterly Injections
Table 13. Global Long-acting Anti-HIV Drugs Sales by Dosing Interval (2021-2026) & (K Dose)
Table 14. Global Long-acting Anti-HIV Drugs Sales Market Share by Dosing Interval (2021-2026)
Table 15. Global Long-acting Anti-HIV Drugs Revenue by Dosing Interval (2021-2026) & ($ million)
Table 16. Global Long-acting Anti-HIV Drugs Revenue Market Share by Dosing Interval (2021-2026)
Table 17. Global Long-acting Anti-HIV Drugs Sale Price by Dosing Interval (2021-2026) & (US$/Dose)
Table 18. Major Players of Original Drug
Table 19. Major Players of Generic Drug
Table 20. Global Long-acting Anti-HIV Drugs Sales by Drug Properties (2021-2026) & (K Dose)
Table 21. Global Long-acting Anti-HIV Drugs Sales Market Share by Drug Properties (2021-2026)
Table 22. Global Long-acting Anti-HIV Drugs Revenue by Drug Properties (2021-2026) & ($ million)
Table 23. Global Long-acting Anti-HIV Drugs Revenue Market Share by Drug Properties (2021-2026)
Table 24. Global Long-acting Anti-HIV Drugs Sale Price by Drug Properties (2021-2026) & (US$/Dose)
Table 25. Global Long-acting Anti-HIV Drugs Sale by Application (2021-2026) & (K Dose)
Table 26. Global Long-acting Anti-HIV Drugs Sale Market Share by Application (2021-2026)
Table 27. Global Long-acting Anti-HIV Drugs Revenue by Application (2021-2026) & ($ million)
Table 28. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2021-2026)
Table 29. Global Long-acting Anti-HIV Drugs Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Long-acting Anti-HIV Drugs Sales by Company (2021-2026) & (K Dose)
Table 31. Global Long-acting Anti-HIV Drugs Sales Market Share by Company (2021-2026)
Table 32. Global Long-acting Anti-HIV Drugs Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Long-acting Anti-HIV Drugs Revenue Market Share by Company (2021-2026)
Table 34. Global Long-acting Anti-HIV Drugs Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Long-acting Anti-HIV Drugs Producing Area Distribution and Sales Area
Table 36. Players Long-acting Anti-HIV Drugs Products Offered
Table 37. Long-acting Anti-HIV Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Long-acting Anti-HIV Drugs Sales by Geographic Region (2021-2026) & (K Dose)
Table 41. Global Long-acting Anti-HIV Drugs Sales Market Share Geographic Region (2021-2026)
Table 42. Global Long-acting Anti-HIV Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Long-acting Anti-HIV Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Long-acting Anti-HIV Drugs Sales by Country/Region (2021-2026) & (K Dose)
Table 45. Global Long-acting Anti-HIV Drugs Sales Market Share by Country/Region (2021-2026)
Table 46. Global Long-acting Anti-HIV Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Long-acting Anti-HIV Drugs Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Dose)
Table 49. Americas Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2026)
Table 50. Americas Long-acting Anti-HIV Drugs Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 52. Americas Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 53. APAC Long-acting Anti-HIV Drugs Sales by Region (2021-2026) & (K Dose)
Table 54. APAC Long-acting Anti-HIV Drugs Sales Market Share by Region (2021-2026)
Table 55. APAC Long-acting Anti-HIV Drugs Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 57. APAC Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 58. Europe Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Dose)
Table 59. Europe Long-acting Anti-HIV Drugs Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 61. Europe Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 62. Middle East & Africa Long-acting Anti-HIV Drugs Sales by Country (2021-2026) & (K Dose)
Table 63. Middle East & Africa Long-acting Anti-HIV Drugs Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Long-acting Anti-HIV Drugs Sales by Type (2021-2026) & (K Dose)
Table 65. Middle East & Africa Long-acting Anti-HIV Drugs Sales by Application (2021-2026) & (K Dose)
Table 66. Key Market Drivers & Growth Opportunities of Long-acting Anti-HIV Drugs
Table 67. Key Market Challenges & Risks of Long-acting Anti-HIV Drugs
Table 68. Key Industry Trends of Long-acting Anti-HIV Drugs
Table 69. Long-acting Anti-HIV Drugs Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Long-acting Anti-HIV Drugs Distributors List
Table 72. Long-acting Anti-HIV Drugs Customer List
Table 73. Global Long-acting Anti-HIV Drugs Sales Forecast by Region (2027-2032) & (K Dose)
Table 74. Global Long-acting Anti-HIV Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Long-acting Anti-HIV Drugs Sales Forecast by Country (2027-2032) & (K Dose)
Table 76. Americas Long-acting Anti-HIV Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Long-acting Anti-HIV Drugs Sales Forecast by Region (2027-2032) & (K Dose)
Table 78. APAC Long-acting Anti-HIV Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Long-acting Anti-HIV Drugs Sales Forecast by Country (2027-2032) & (K Dose)
Table 80. Europe Long-acting Anti-HIV Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Long-acting Anti-HIV Drugs Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Middle East & Africa Long-acting Anti-HIV Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Long-acting Anti-HIV Drugs Sales Forecast by Type (2027-2032) & (K Dose)
Table 84. Global Long-acting Anti-HIV Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Long-acting Anti-HIV Drugs Sales Forecast by Application (2027-2032) & (K Dose)
Table 86. Global Long-acting Anti-HIV Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. ViiV Healthcare Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 89. ViiV Healthcare Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. ViiV Healthcare Main Business
Table 91. ViiV Healthcare Latest Developments
Table 92. Janssen Pharmaceuticals Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 94. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. Janssen Pharmaceuticals Main Business
Table 96. Janssen Pharmaceuticals Latest Developments
Table 97. Gilead Sciences Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 99. Gilead Sciences Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Gilead Sciences Main Business
Table 101. Gilead Sciences Latest Developments
Table 102. Theratechnologies Basic Information, Long-acting Anti-HIV Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Theratechnologies Long-acting Anti-HIV Drugs Product Portfolios and Specifications
Table 104. Theratechnologies Long-acting Anti-HIV Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Theratechnologies Main Business
Table 106. Theratechnologies Latest Developments
LIST OF FIGURES
Figure 1. Picture of Long-acting Anti-HIV Drugs
Figure 2. Long-acting Anti-HIV Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Long-acting Anti-HIV Drugs Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Long-acting Anti-HIV Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Long-acting Anti-HIV Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Long-acting Anti-HIV Drugs Sales Market Share by Country/Region (2025)
Figure 10. Long-acting Anti-HIV Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Single Drug
Figure 12. Product Picture of Combination Preparation
Figure 13. Global Long-acting Anti-HIV Drugs Sales Market Share by Type in 2026
Figure 14. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Short-interval Injections
Figure 16. Product Picture of Monthly Injections
Figure 17. Product Picture of Quarterly Injections
Figure 18. Global Long-acting Anti-HIV Drugs Sales Market Share by Dosing Interval in 2026
Figure 19. Global Long-acting Anti-HIV Drugs Revenue Market Share by Dosing Interval (2021-2026)
Figure 20. Product Picture of Original Drug
Figure 21. Product Picture of Generic Drug
Figure 22. Global Long-acting Anti-HIV Drugs Sales Market Share by Drug Properties in 2026
Figure 23. Global Long-acting Anti-HIV Drugs Revenue Market Share by Drug Properties (2021-2026)
Figure 24. Long-acting Anti-HIV Drugs Consumed in Hospital
Figure 25. Global Long-acting Anti-HIV Drugs Market: Hospital (2021-2026) & (K Dose)
Figure 26. Long-acting Anti-HIV Drugs Consumed in Clinic
Figure 27. Global Long-acting Anti-HIV Drugs Market: Clinic (2021-2026) & (K Dose)
Figure 28. Long-acting Anti-HIV Drugs Consumed in Other
Figure 29. Global Long-acting Anti-HIV Drugs Market: Other (2021-2026) & (K Dose)
Figure 30. Global Long-acting Anti-HIV Drugs Sale Market Share by Application (2025)
Figure 31. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application in 2025
Figure 32. Long-acting Anti-HIV Drugs Sales by Company in 2025 (K Dose)
Figure 33. Global Long-acting Anti-HIV Drugs Sales Market Share by Company in 2025
Figure 34. Long-acting Anti-HIV Drugs Revenue by Company in 2025 ($ millions)
Figure 35. Global Long-acting Anti-HIV Drugs Revenue Market Share by Company in 2025
Figure 36. Global Long-acting Anti-HIV Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Long-acting Anti-HIV Drugs Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 39. Americas Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 40. APAC Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 41. APAC Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 42. Europe Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 43. Europe Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 45. Middle East & Africa Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 46. Americas Long-acting Anti-HIV Drugs Sales Market Share by Country in 2025
Figure 47. Americas Long-acting Anti-HIV Drugs Revenue Market Share by Country (2021-2026)
Figure 48. Americas Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 49. Americas Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 50. United States Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Long-acting Anti-HIV Drugs Sales Market Share by Region in 2025
Figure 55. APAC Long-acting Anti-HIV Drugs Revenue Market Share by Region (2021-2026)
Figure 56. APAC Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 57. APAC Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 58. China Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. India Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Long-acting Anti-HIV Drugs Sales Market Share by Country in 2025
Figure 66. Europe Long-acting Anti-HIV Drugs Revenue Market Share by Country (2021-2026)
Figure 67. Europe Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 68. Europe Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 69. Germany Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. France Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 77. Egypt Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drugs in 2026
Figure 83. Manufacturing Process Analysis of Long-acting Anti-HIV Drugs
Figure 84. Industry Chain Structure of Long-acting Anti-HIV Drugs
Figure 85. Channels of Distribution
Figure 86. Global Long-acting Anti-HIV Drugs Sales Market Forecast by Region (2027-2032)
Figure 87. Global Long-acting Anti-HIV Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Long-acting Anti-HIV Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Long-acting Anti-HIV Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Long-acting Anti-HIV Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Long-acting Anti-HIV Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Long-acting Anti-HIV Drugs
Figure 2. Long-acting Anti-HIV Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Long-acting Anti-HIV Drugs Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Long-acting Anti-HIV Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Long-acting Anti-HIV Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Long-acting Anti-HIV Drugs Sales Market Share by Country/Region (2025)
Figure 10. Long-acting Anti-HIV Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Single Drug
Figure 12. Product Picture of Combination Preparation
Figure 13. Global Long-acting Anti-HIV Drugs Sales Market Share by Type in 2026
Figure 14. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Short-interval Injections
Figure 16. Product Picture of Monthly Injections
Figure 17. Product Picture of Quarterly Injections
Figure 18. Global Long-acting Anti-HIV Drugs Sales Market Share by Dosing Interval in 2026
Figure 19. Global Long-acting Anti-HIV Drugs Revenue Market Share by Dosing Interval (2021-2026)
Figure 20. Product Picture of Original Drug
Figure 21. Product Picture of Generic Drug
Figure 22. Global Long-acting Anti-HIV Drugs Sales Market Share by Drug Properties in 2026
Figure 23. Global Long-acting Anti-HIV Drugs Revenue Market Share by Drug Properties (2021-2026)
Figure 24. Long-acting Anti-HIV Drugs Consumed in Hospital
Figure 25. Global Long-acting Anti-HIV Drugs Market: Hospital (2021-2026) & (K Dose)
Figure 26. Long-acting Anti-HIV Drugs Consumed in Clinic
Figure 27. Global Long-acting Anti-HIV Drugs Market: Clinic (2021-2026) & (K Dose)
Figure 28. Long-acting Anti-HIV Drugs Consumed in Other
Figure 29. Global Long-acting Anti-HIV Drugs Market: Other (2021-2026) & (K Dose)
Figure 30. Global Long-acting Anti-HIV Drugs Sale Market Share by Application (2025)
Figure 31. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application in 2025
Figure 32. Long-acting Anti-HIV Drugs Sales by Company in 2025 (K Dose)
Figure 33. Global Long-acting Anti-HIV Drugs Sales Market Share by Company in 2025
Figure 34. Long-acting Anti-HIV Drugs Revenue by Company in 2025 ($ millions)
Figure 35. Global Long-acting Anti-HIV Drugs Revenue Market Share by Company in 2025
Figure 36. Global Long-acting Anti-HIV Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Long-acting Anti-HIV Drugs Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 39. Americas Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 40. APAC Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 41. APAC Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 42. Europe Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 43. Europe Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Long-acting Anti-HIV Drugs Sales 2021-2026 (K Dose)
Figure 45. Middle East & Africa Long-acting Anti-HIV Drugs Revenue 2021-2026 ($ millions)
Figure 46. Americas Long-acting Anti-HIV Drugs Sales Market Share by Country in 2025
Figure 47. Americas Long-acting Anti-HIV Drugs Revenue Market Share by Country (2021-2026)
Figure 48. Americas Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 49. Americas Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 50. United States Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Long-acting Anti-HIV Drugs Sales Market Share by Region in 2025
Figure 55. APAC Long-acting Anti-HIV Drugs Revenue Market Share by Region (2021-2026)
Figure 56. APAC Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 57. APAC Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 58. China Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. India Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Long-acting Anti-HIV Drugs Sales Market Share by Country in 2025
Figure 66. Europe Long-acting Anti-HIV Drugs Revenue Market Share by Country (2021-2026)
Figure 67. Europe Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 68. Europe Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 69. Germany Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. France Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Long-acting Anti-HIV Drugs Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Long-acting Anti-HIV Drugs Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Long-acting Anti-HIV Drugs Sales Market Share by Application (2021-2026)
Figure 77. Egypt Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Long-acting Anti-HIV Drugs Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drugs in 2026
Figure 83. Manufacturing Process Analysis of Long-acting Anti-HIV Drugs
Figure 84. Industry Chain Structure of Long-acting Anti-HIV Drugs
Figure 85. Channels of Distribution
Figure 86. Global Long-acting Anti-HIV Drugs Sales Market Forecast by Region (2027-2032)
Figure 87. Global Long-acting Anti-HIV Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Long-acting Anti-HIV Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Long-acting Anti-HIV Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Long-acting Anti-HIV Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Long-acting Anti-HIV Drugs Revenue Market Share Forecast by Application (2027-2032)
